Admedus Limited
(ASX:AHZ) has launched CardioCel in Malaysia and the company has achieved its first sale.
The launch in Malaysia is part of an ongoing global rollout of CardioCel. Alongside Malaysia, CardioCel is now available in Europe, USA, Canada, Hong Kong, Singapore and continues to be accessed in Australia via early access programs.
CardioCel is a bio-scaffold used to repair and treat cardiovascular defects including reconstructing and repairing heart valves to retain their native function.
Admedus CEO Lee Rodne said the availability of the product in the coming quarters will add to the growing sources of revenue in this financial year.
Admedus reported a net loss of $26.8 million at 30 Sep 2015.
